Advanced Search

Study Preview



Study Title and Description

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.



Key Questions Addressed
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Author Andreone P., Colombo MG., Enejosa JV., Koksal I., Ferenci P., Maieron A., Müllhaupt B., Horsmans Y., Weiland O., Reesink HW., Rodrigues L., Hu YB., Podsadecki T., Bernstein B.
Country University of Bologna, Bologna, Italy. Electronic address: pietro.andreone@unibo.it.
Year 2014
Numbers Pubmed ID: 24818763

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.